2010 Update: Guidelines for the management of benign prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q42413446

about

Microwave thermotherapy for benign prostatic hyperplasia Korean clinical practice guideline for benign prostatic hyperplasia A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms Update on medical therapy for male LUTS Randomized, controlled trial of laser vs. bipolar plasma vaporization treatment of benign prostatic hyperplasia.Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year r Association of Suicidality and Depression With 5α-Reductase Inhibitors.New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers.Systematic review of clinical features of suspected prostate cancer in primary care.Canadian trend in surgical management of benign prostatic hyperplasia and laser therapy from 2007-2008 to 2011-2012.Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?Assessment of photoselective vaporization of prostate skills during Urology Objective Structured Clinical Examinations (OSCE)Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis.Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.Current status of 5α-reductase inhibitors in prostate disease management Management of large prostatic adenoma: Lasers versus bipolar transurethral resection of prostate.Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.Urological resident exposure to transurethral surgical options for BPH management in 2012-2013: A pan-Canadian survey.Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.Medical management of benign prostatic hyperplasia: Results from a population-based study.Lower urinary tract symptoms in a 66-year-old man The association between the ICIQ-LUTS and the ICIQ-bladder diary in assessing LUTS.Urodynamics of men with urinary retention.The International Prostate Symptom Score (IPSS) Is an Inadequate Tool to Screen for Urethral Stricture Recurrence After Anterior Urethroplasty.Picking your prostates.Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.The Modulating Effects of Benign Prostate Enlargement Medications on Upgrading Predictors in Patients with Gleason 6 at Biopsy.Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.Association between SRD5A2 rs523349 and rs9282858 Polymorphisms and Risk of Benign Prostatic Hyperplasia: A Meta-Analysis.Let's not forget about TUIP: A highly underutilized, minimally-invasive and durable technique for men with <30 g prostates.TURP in the new century: an analytical reappraisal in light of lasers.Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway.Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the manage Photoselective vaporization of the prostate with the 180-W XPS-Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes.A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.Drugs for benign prostatic hypertrophy

P2860

Q24200487-82F763A1-4C9E-4B97-8DD1-638C06F8FC03 Q26766302-B8C7EF08-66A6-4FFC-8C73-E18B0E7090C7 Q26798012-6BF957C4-B940-40B3-87A3-4AFEDB80BE6A Q26862710-6413ADEF-A5CF-473F-9AA8-707E9C3363D2 Q33803807-B682C27B-B97D-4091-8BC8-361F77CB710D Q34377799-F0F264AB-A83A-4F1D-8D65-F64A5A8F5914 Q34553657-FF544D02-08D7-4EAB-BE09-4B32CE26ED70 Q34635165-90E7BCF7-A660-4325-BE39-CB0AC2AF487A Q34994782-5437236B-3C74-49BC-8809-55FE017DDA3E Q34994815-327E9B38-0831-4D7C-AC47-EFC3DE869CF6 Q34998408-38E5A6AB-D5AA-4FDF-92EF-8C02E4241DB2 Q35050805-E5753B13-CA9C-4AD6-9084-0ED9524250DA Q35106388-CD0CEDD0-642A-4B08-A3BF-119B8826E01F Q35686476-316126F5-36B0-4C4B-BC2B-AD90977DDFE0 Q35689075-96098BBF-AA6B-4D0C-A0F6-35BD7F43F563 Q35989759-79DD9A9C-0D28-4BED-B71A-700F84C80EB6 Q36778346-B2F055D3-06BF-4F96-BD8D-28DE37159303 Q37198971-64848B44-EA1B-4FF3-BA3E-F059DC5B9694 Q37496437-159967EC-B855-4728-8B5F-592586047452 Q37593743-D2AAA616-8D16-4CD2-81A1-F069C3B04D4D Q37875062-658270F4-BDA1-46A7-99EC-799A9E595E17 Q38682496-6BF35737-9081-430D-BD4B-6E3D46642EA2 Q38747352-DD399EB7-4506-4946-A26D-05B856D2EE1A Q39236229-4A310527-0B20-4A3D-B5D3-8C066A0D74D7 Q39421320-020664B8-7D1B-4CA8-8192-C8DE5650138B Q39826406-E07CFB64-A096-4C7E-9E82-C6C15766CA27 Q40936371-8E5BE2F8-2843-4791-8DBB-23B3F859932E Q41092813-33E0B491-B974-41C9-BCA8-A7BFB02BDAE6 Q41126233-FE47AB4D-B0ED-44B6-AF68-0BA2C5A19771 Q41333008-B3A10C8A-F8AB-4148-A3A9-CB86A992BCEB Q41684535-1681AECF-9B3B-4952-ABEB-DB642A64799F Q41906222-EF516807-EBAD-48C4-8C99-1EB20F7CE72E Q42413456-B359B2C2-7778-4B4B-B564-7C3536D87BE5 Q43353576-AC2D6AE5-64D3-43E4-84F3-EED892FC3EA4 Q43902268-DED19146-3668-415D-AE86-A93733E0F4A3 Q52617227-E5777E84-4ABE-4D85-8EBA-144110B197A0 Q55380284-2684EE77-78DF-407C-852E-D4F8E8B4322F Q58588902-A84E2C40-ABD9-4C68-9A4D-E93B8D4C1AB9

P2860

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q42413446

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@en

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@nl

type

label

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@en

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@nl

prefLabel

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@en

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@nl

P1433

Q42413446-F813F89A-67ED-4114-8376-ADC6350BC7EE

P1476

Q42413446-9DDAF7E6-6C64-48D3-8E00-DBECFB940B29

P2093

Q42413446-4BC49520-2B8B-4D63-8528-EB96E9513853

Q42413446-8CEA9E95-55B0-4514-BECB-E91F9CEC7A6D

Q42413446-A0637C39-2A42-4784-8E1B-178FB582E6B9

Q42413446-AF95A063-8EDF-477B-8133-B5D8CA17CEC5

Q42413446-B7825EF9-F3CF-4C7B-9316-4BBD16F5956D

P2860

Q42413446-0826B8AD-36D5-444D-9B70-591012EA96A6

Q42413446-0A9C97C9-FFE2-4CF1-9AF7-6A83B5669C66

Q42413446-0FE68B44-3716-404C-8926-50087DE50BDF

Q42413446-1994643E-0DD2-48FD-B1C8-7A63A17AEA12

Q42413446-1A67F1BC-462A-4833-A113-535C1693BA7B

Q42413446-1AD8EA14-49EF-4FE9-9486-EB3FE958ECB5

Q42413446-1C1CBDC3-9398-46A5-B517-6CA769910D86

Q42413446-1C3D7074-70D5-4828-AC22-A033E8A49E38

Q42413446-1E646705-F92C-40F0-8B65-05DFBCFC87A8

Q42413446-21847FC6-16D1-4575-A2A5-F2F9AC731A84

P304

Q42413446-09BCC870-2B91-4229-BCA9-7BDA81FDDD38

P31

Q42413446-B664DAE1-BD01-487F-8A79-37A382AF51E3

P356

Q42413446-6CBABAC3-C774-416C-BD64-1E63F9FCADC9

P433

Q42413446-95B917DE-6664-4F8C-9054-F700DC3885D5

P478

Q42413446-1E1087BA-4F1A-4073-BE5F-21A9272F767C

P577

Q42413446-4EF241BF-92CB-416B-9ABC-6497C4715A79

P5875

Q42413446-EE0B8555-2F20-47C1-B74B-EA2656240976

P698

Q42413446-9DADF19B-D9C0-415A-9698-FA455B754086

P932

Q42413446-0495E948-27C3-4CA4-A966-4FB689517E43

P356

P1433

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

P1476

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

@en

P2093

Carlos E Méndez-Probst

http://www.w3.org/2001/XMLSchema#string

Hassan Razvi

http://www.w3.org/2001/XMLSchema#string

J Curtis Nickel

http://www.w3.org/2001/XMLSchema#string

Ryan F Paterson

http://www.w3.org/2001/XMLSchema#string

Thomas F Whelan

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

Saw palmetto for benign prostatic hyperplasia

Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia

Effect of dutasteride on the risk of prostate cancer.

Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.:: a randomized prospective trial of 120 patients.

Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options.

Terazosin for benign prostatic hyperplasia.

Interstitial laser coagulation versus transurethral resection of the prostate for benign prostatic enlargement--a prospective randomized study.

A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia.

P304

310-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5489/CUAJ.10124

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47415653

http://www.w3.org/2001/XMLSchema#string

P698

20944799

http://www.w3.org/2001/XMLSchema#string

P932

2950766

http://www.w3.org/2001/XMLSchema#string